TrialNature communications2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Maria Pouyiourou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
26 papers cite it
this paperpooled ittrialcites it